Lakeway, NY -- (SBWIRE) -- 02/25/2013 -- ThePennyStockProfiler.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-
Caesars Entertainment Corp (NASDAQ:CZR) shares jumped 2.42% to $11.87. The company recently said it is proud to present the Atlantic City Food and Wine Festival's fifth annual celebration, beginning Thursday, July 25, with events taking place throughout the weekend.
Additionally, the company will host a conference call at 2 p.m. Pacific Time Monday, February 25, 2013, to review its fourth-quarter and full-year results.
Is CZR a Strong Buy After The Recent Slump? Let’s Find out Here
Deutsche Bank AG (USA) (NYSE:DB) shares climbed 4.62% to $49.17. The company plans to tell employees it will impose a 300,000-euro ($409,000) cap on bonuses being paid this year, said three people with knowledge of the discussions on Feb. 1. The cap, which will apply across the company, may be relayed to employees next week, said the people, who asked not to be identified because the plans are private. Senior staff, or what the bank calls “regulated” employees, will receive as much as 150,000 euros in cash, with the balance available in shares in August.
Is DB a Strong Buying Opportunity After The Recent Slump? Find out Here
Affymax, Inc. (NASDAQ:AFFY) shares plunged 84.02% to $2.64. after Affymax and Takeda Pharmaceutical announced today that they have decided to voluntarily recall all lots of OMONTYS Injection to the user level, as a result of new postmarketing reports regarding serious hypersensitivity reactions, including anaphylaxis.
Additionally, JMP Securities lowered shares of AFFY from an outperform rating to an underperform rating in a research report released today. JMP Securities currently has $2.50 price target on the stock.
Should Investors Consider AFFY After The Recent price Action? Get Free Trend Analysis Here
Dynavax Technologies Corporation (NASDAQ:DVAX) shares dropped 34.34% to $1.95. The company today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA or Agency) regarding its Biologic License Application (BLA) for HEPLISAV, an investigational adult hepatitis B vaccine. In the CRL, the FDA specified that the indication in adults 18-70 years of age cannot be approved without further evaluation of safety in this broad age group.
Get latest News, Updates on DVAX Here
ThePennyStockProfiler.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. ThePennyStockProfiler.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.ThePennyStockProfiler.com
The assembled information disseminated by ThePennyStockProfiler.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. ThePennyStockProfiler.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)